ONCT
ONCTERNAL THERAPEUTICS INC (ONCT)
$0.9101
Market is closedMarket is closed – opens on 8 PM, 01 Dec 2022
– opens on 8 PM, 01 Dec 2022
Key Stats
$0.9
Day's Range
$0.972999
$0.6902
52-Week Range
$3.08
| Returns | |
| 1 month return | 13.32% |
| 3 month return | 18.74% |
| 1 year return | 67.5% |
| 5 year return | 93.0% |
Company Information
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes cirmtuzumab, an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer. The clinical pipeline also includes TK216, an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program utilizing the cirmtuzumab antibody backbone to develop a CAR-T therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors.
| Organization | ONCTERNAL THERAPEUTICS INC |
| Employees | 26 |
| CEO | Dr. James B. Breitmeyer M.D., Ph.D. |
| Industry | Biotechnology |
Analyst Recommendation
based on 4 analysts ratings
Buy
100%
Buy
0%
Hold
0%
Sell
Based on 4 Wall street analysts offering stock ratings for ONCTERNAL THERAPEUTICS INC(by analysts ranked 0 to 5 stars)
Analyst Forecast
What analysts predicted
Upside of 877.91%Current
$0.91
Target
$8.9
Recommendation Trend
Based on 4 analyst
| Current | 1M Ago | 3M Ago | |
| Buy | 4 | 11 | 11 |
| Hold | 0 | 1 | 1 |
| Sell | 0 | 0 | 0 |
| Consensus | BUY | BUY | BUY |
Highlights
| Market Capitalization | 52.9M |
| Book Value | $1.24 |
| Dividend Share | 0.0 |
| Dividend Yield | 0.0% |
| Earnings Per Share (EPS) | -0.71 |
| Wall Street Target Price | 8.9 |
Valuation
| Trailing PE | 0.0 |
| Forward PE | 0.0 |
| Price/Book (mrq) | 0.79 |
| Enterprise Value | -16478796 |
| Enterprise Value/Revenue | 0.85 |
| Enterprise Value/Ebitda | 0.4 |
Technicals
| Beta | 1.44 |
| 50 Day MA | 0.98 |
| 200 Day MA | 1.17 |
Institutional Holdings
Vanguard Group Inc
5.08%
Millennium Management LLC
2.3%
Citadel Advisors Llc
2.06%
Renaissance Technologies Corp
1.14%
Geode Capital Management, LLC
0.73%
Brighton Jones LLC
0.59%
Discover more
Frequently Asked Questions
What is ONCTERNAL THERAPEUTICS INC share price today?
Can Indians buy ONCTERNAL THERAPEUTICS INC shares?
How can I buy ONCTERNAL THERAPEUTICS INC shares from India?
Can Fractional shares of ONCTERNAL THERAPEUTICS INC be purchased?
What are the documents required to start investing in ONCTERNAL THERAPEUTICS INC stocks?
What are today’s High and Low prices of ONCTERNAL THERAPEUTICS INC?
What are today’s traded volumes of ONCTERNAL THERAPEUTICS INC?
What is today’s market capitalisation of ONCTERNAL THERAPEUTICS INC?
What is the 52 Week High and Low Range of ONCTERNAL THERAPEUTICS INC?
How much percentage ONCTERNAL THERAPEUTICS INC is down from its 52 Week High?
How much percentage ONCTERNAL THERAPEUTICS INC is up from its 52 Week low?
What are the historical returns of ONCTERNAL THERAPEUTICS INC?
Who is the Chief Executive Officer (CEO) of ONCTERNAL THERAPEUTICS INC?
Trading and brokerage services provided by
Banking and Remittance services provided by
Technology services provided by : Finzoomers Services Private Limited
Disclaimer: These services are not for exchange traded products.The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Finzoomers Services Private Limited acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*